Reactivity against microsatellite instability-induced frameshift mutations in patients with inflammatory bowel disease

Table 2 Influence of various characteristics on frameshift-peptides-specific immune response

Influence of different characteristics on reactivity	P value
Duration of disease ( </> 7 yr)	0.023 (χ2)
Duration of disease (IBD)	0.002 (Mann-Whitney U)
Duration of disease (IBD without azathioprine)	0.008 (Mann-Whitney U)
Duration of disease (IBD with weak reactivity)	0.006 (Mann-Whitney U)
Duration of disease (IBD with strong reactivity)	0.005 (Mann-Whitney U)
Duration of azathioprine (among patients with azathioprine)	0.476 (Mann-Whitney U)
Duration of azathioprine (IBD with azathioprine and weak reactivity)	0.600 (Mann-Whitney U)
Duration of azathioprine (IBD with azathioprine and strong reactivity)	0.350 (Mann-Whitney U)
IBD controls vs healthy controls	0.001 (χ2)
IBD with azathioprine vs healthy controls	0.001 (χ2)
IBD with azathioprine vs IBD controls	0.032 (χ2)
IBD with azathioprine vs IBD controls (weak reactivity)	0.007 (χ2)
IBD with azathioprine vs IBD controls (strong reactivity)	0.342 (χ2)
Gender (male vs female)	0.491 (χ2)
Age	0.522 (Mann-Whitney U)
Smoking status	0.426 (χ2)
Disease pattern of CD (small bowel vs large bowel vs combined)	0.219 (χ2)
Disease pattern of UC (left sided colitis vs pancolitis)	0.412 (χ2)
Positive family anamnesis	0.618 (χ2)
Co-medication:	(χ2)
Prednisolone	0.356
TNF-α-antibody	0.336
Tacrolimus	0.497
Methotrexate	0.617

IBD: Inflammatory bowel disease; UC: Ulcerative colitis; CD: Crohn’s disease.